TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07648472: A Single-Arm, Open-Label, Dose Escalation Phase I Study of OVV-01 Intravenous and Intratumoral Injection to Evaluate the Safety, Tolerability, and Preliminary Efficacy in Patients With Advanced Solid Tumors

Sponsor: Joint Biosciences Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07648472 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07648472 Rescue Dossier →